Diabetes & metabolism journalSep 10, 2026

Addressing Muscle Loss Risks in Treatments That Lower Blood Sugar

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Sep 11, 2026

Abstract

Incretin-based therapies produce a weight-loss magnitude previously achievable only through intensive caloric restriction or bariatric surgery.

Weight loss from incretin-based therapies is associated with preferential reduction of fat mass and relative preservation of lean mass.
Loss of lean body mass during therapy does not necessarily indicate equivalent loss of skeletal muscle or sarcopenia.
Incretin therapies may improve muscle quality by reducing fat within muscles, known as myosteatosis.
Current evidence does not demonstrate obvious functional harm related to muscle strength or physical performance from these therapies.
Long-term data on the effects of incretin therapies in individuals with reduced muscle reserve remain limited.

Simplified

Incretin-based therapies have transformed the treatment of type 2 diabetes mellitus and obesity by producing a weight-loss magnitude that was previously achievable only through intensive caloric restriction or bariatric surgery. This therapeutic shift has moved the clinical focus from the quantity of weight loss to the quality of weight loss. Lean mass reduction is frequently observed during weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs), dual glucose-dependent insulinotropic polypeptide/GLP-1RAs, or emerging multi-agonists. However, loss of lean body mass does not necessarily indicate equivalent loss of contractile skeletal muscle or sarcopenia. Incretin-based therapy is generally associated with preferential fat mass reduction, relative preservation of lean mass, and potential improvement in muscle quality through reduced myosteatosis. Thus, the clinically relevant question is whether incretin-associated body-composition changes lead to deterioration in muscle strength or physical performance, an increased risk of falls or fractures, or impaired quality of life. Available evidence does not show obvious functional harm; however, long-term data remain limited, especially in people with reduced muscle reserve. A muscle-conscious approach that integrates body-composition assessment, functional monitoring, resistance training, nutritional optimization, and emerging pharmacologic muscle-preserving strategies is needed to achieve high-quality weight loss.

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

GLP-1 TherapiesIssue #54

GLP-1 drugs don't build habits — and that gap is costing patients their results

↗

Addressing Muscle Loss Risks in Treatments That Lower Blood Sugar

Abstract

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief